Proof in Practice
See how leading biotech companies are accelerating drug discovery with Embyr's integrated platform.
MASH / Liver Disease
Accelerating Target Discovery for MASH Under Partner Pressure
5 compounds analyzed → 3 leads prioritized in 14 weeks
Oncology / AML
Resolving a Phase II Failure Through Comprehensive On/Off-Target Validation
$200M program rescued — root cause identified in 14 weeks
